Neuren receives Rare Pediatric Disease Designation from FDA
Filed with ASX · · 1 page · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Fast Track granted by FDA for NNZ-2591 in Pitt Hopkins
- Priority Review Voucher sale proceeds received
- Trofinetide marketing application submitted in Europe
- Neuren announces A$50m on-market share buy-back program
- Q3 2024 update
Later from Neuren Pharmaceuticals
- DAYBUE (trofinetide) 2024 net sales US$348 million
- Appendix 4E and 2024 full year accounts
- 2024 results - A$166m comprehensive income for shareholders
- Neuren receives DAYBUE sales milestone payment of US$50m
- Neuren initiates development of NNZ-2591 to treat HIE
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals